Dexmedetomidine for Sedation During Radiological Interventional Procedures

Evaluation of Role of Dexmedetomidine as a Sole Agent in Sedation of Cancer Patients Undergoing Radiological Interventional Procedures

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02180737

Acronym

Dexmed

Enrollment

Registered

2014-07-03

Start date

2014-01-31

Completion date

2015-01-31

Last updated

2016-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Procedural Sedation

Keywords

dexmedetomedine, sedation, interventional radiology

Brief summary

Evaluation of the role of dexmedetomidine as a sole agent in sedating patients undergoing interventional radiological procedures and measuring its different outcome variables.

Interventions

DRUGDexmeditomedine

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Age from 18-65 years old * ASA physical status of I-II * Expected procedure lasting at least 30 minutes

Exclusion criteria

* Unstable cardiac status (life-threatening arrhythmias, abnormal cardiac anatomy, significant cardiac dysfunction and third-degree heart block. * An alpha2-agonist or antagonist within 14 days before the scheduled procedure. * patients received an IV opioid within 1 h, or an oral or IM opioid within 4 h of the start of study drug administration. * Patients who are allergic to Dexmedetomidine or alpha 2-agonists.

Design outcomes

Primary

Measure	Time frame	Description
Degree of sedation	1 hour	It will be measured and recorded by using the Ramsay sedation score.
verbal analogue scale	1 hour	assessment of pain using VAS score

Secondary

Measure	Time frame	Description
patient satisfaction	24 hours	assessment of patient satisfaction by 4 point scale

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026